An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19

A Novel Coronavirus from Patients with Pneumonia in China, 2019

(2020) Na Zhu et al.   NEW ENGLAND JOURNAL OF MEDICINE

In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

(2020) Xueting Yao et al.   CLINICAL INFECTIOUS DISEASES

Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial

(2020) Minh Patrick Lê et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

(2020) Fei Zhou et al.   LANCET

A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19

(2020) Bin Cao et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro

(2020) Jia Liu et al.   Cell Discovery

Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations

(2020) Catia Marzolini et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro

(2020) Ka-Tim Choy et al.   ANTIVIRAL RESEARCH

Type 1 interferons as a potential treatment against COVID-19

(2020) Erwan Sallard et al.   ANTIVIRAL RESEARCH

Physiologically‐Based Pharmacokinetic Modeling to Predict the Clinical Efficacy of the Coadministration of Lopinavir and Ritonavir against SARS‐CoV‐2

(2020) Aarzoo Thakur et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Interferon-β-1a Inhibition of Severe Acute Respiratory Syndrome–Coronavirus 2 In Vitro When Administered After Virus Infection

(2020) Nicola Clementi et al.   JOURNAL OF INFECTIOUS DISEASES

Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates

(2020) Pauline Maisonnasse et al.   NATURE

Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19

(2020) Alexandre B. Cavalcanti et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

(2020) Peter W Horby et al.   LANCET

Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19

(2020)   NEW ENGLAND JOURNAL OF MEDICINE

Protocol for the DisCoVeRy trial: multicentre, adaptive, randomised trial of the safety and efficacy of treatments for COVID-19 in hospitalised adults

(2020) Florence Ader   BMJ Open

Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results

(2020)   NEW ENGLAND JOURNAL OF MEDICINE

Simultaneous quantitation of hydroxychloroquine and its metabolites in mouse blood and tissues using LC–ESI–MS/MS: An application for pharmacokinetic studies

(2018) Yashpal S. Chhonker et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-β1b (MIRACLE trial): study protocol for a randomized controlled trial

(2018) Yaseen M. Arabi et al.   Trials

Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys

(2016) Travis K. Warren et al.   NATURE

Screening of an FDA-Approved Compound Library Identifies Four Small-Molecule Inhibitors of Middle East Respiratory Syndrome Coronavirus Replication in Cell Culture

(2014) Adriaan H. de Wilde et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Immune Activation Mediated Change in Alpha-1-Acid Glycoprotein: Impact on Total and Free Lopinavir Plasma Exposure

(2011) Ighovwerha Ofotokun et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Lopinavir/Ritonavir

(2010) Jamie D. Croxtall et al.   DRUGS